Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT07354074 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia
Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

Interventions

DRUG: Asciminib single agent

Sponsor

Novartis Pharmaceuticals